Douglas Williams

Director at Climb Bio.

Wellesley Hills, MA
Climb Bio

Raised on Climb Bio filings

$110.1M

of $110.1M offered across 1 Form D filing

Form D filings: 1
Teammates: 8
Last filing: May 4, 2026

Company

Biotech · Wellesley Hills, MA

B-cell depleting antibodies for autoimmune disease

B-cell depleting antibodies for autoimmune disease

Investors: 22

Investors: 22
Sector: Biotech
HQ: Wellesley Hills, MA

Climb Bio filings

Climb Bio Form D filings
Filed	Security	Sold of offered	Filing
May 4, 2026	Equity	$110.1M/ $110.1M	Form D

EquityFiled May 4, 2026Form D
$110.1M/ $110.1M

Works with

Also named on Climb Bio filings

Aoife BrennanPresident and Chief Executive Officer, Form D signerForm D signer Kimberlee DrapkinDirector Alexander (Bo) ComboDirector Andrew LevinDirector Judith DunnDirector Perrin WilsonExecutive Officer Stephen ThomasDirector Susan AltschullerExecutive Officer